{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jones G"],"funding":["National Heart, Lung, and Blood Institute","NHLBI NIH HHS"],"pagination":["1649-1662"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9869290"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(22)"],"pubmed_abstract":["<b>Aim:</b> To characterize the pharmacokinetics of deferoxamine-conjugated nanoparticles (DFO-NPs), a novel nanochelator for removing excess iron. <b>Materials & methods:</b> The pharmacokinetics of DFO-NPs were evaluated in Sprague-Dawley rats at three doses (3.3, 10 and 30 μmol/kg) after intravenous and subcutaneous administration. <b>Results:</b> DFO-NPs exhibited a biphasic concentration-time profile after intravenous administration with a short terminal half-life (2.0-3.2 h), dose-dependent clearance (0.111-0.179 l/h/kg), minimal tissue distribution and exclusive renal excretion with a possible saturable reabsorption mechanism. DFO-NPs after subcutaneous administration exhibited absorption-rate-limited kinetics with a prolonged half-life (5.7-10.1 h) and favorable bioavailability (47-107%). <b>Conclusion:</b> DFO-NPs exhibit nonlinear pharmacokinetics with increasing dose, and subcutaneous administration substantially improves drug exposure, thereby making it a clinically viable administration route for iron chelation."],"journal":["Nanomedicine (London, England)"],"pubmed_title":["Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats."],"pmcid":["PMC9869290"],"funding_grant_id":["HL143020","R01 HL143020"],"pubmed_authors":["Kang H","Zeng L","Choi HS","Jones G","Park SH","Kim J","Stiles WR"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.","description":"<b>Aim:</b> To characterize the pharmacokinetics of deferoxamine-conjugated nanoparticles (DFO-NPs), a novel nanochelator for removing excess iron. <b>Materials & methods:</b> The pharmacokinetics of DFO-NPs were evaluated in Sprague-Dawley rats at three doses (3.3, 10 and 30 μmol/kg) after intravenous and subcutaneous administration. <b>Results:</b> DFO-NPs exhibited a biphasic concentration-time profile after intravenous administration with a short terminal half-life (2.0-3.2 h), dose-dependent clearance (0.111-0.179 l/h/kg), minimal tissue distribution and exclusive renal excretion with a possible saturable reabsorption mechanism. DFO-NPs after subcutaneous administration exhibited absorption-rate-limited kinetics with a prolonged half-life (5.7-10.1 h) and favorable bioavailability (47-107%). <b>Conclusion:</b> DFO-NPs exhibit nonlinear pharmacokinetics with increasing dose, and subcutaneous administration substantially improves drug exposure, thereby making it a clinically viable administration route for iron chelation.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-04T22:56:19.717Z","creation":"2025-04-04T22:56:19.717Z"},"accession":"S-EPMC9869290","cross_references":{"pubmed":["36547231"],"doi":["10.2217/nnm-2022-0159"]}}